English
简体中文
Total: £ 56.28
Published Date: 2025-09-10 | Pages: 81 | Tables: 82 | Pharma & Healthcare
The global market for Transdermal Scopolamine was valued at US$ 428 million in the year 2024 and is projected to reach a revised size of US$ 585 million by 2031, growing at a CAGR of 4.6% during the forecast period.
Scopolamine transdermal patch is used to prevent nausea and vomiting after anesthesia, narcotic pain medicines, and surgery. It is also used to prevent nausea and vomiting caused by motion sickness. Scopolamine belongs to the group of medicines called anticholinergics.
The fluctuation of upstream raw material prices has a significant impact on product prices.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Transdermal Scopolamine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transdermal Scopolamine.
The Transdermal Scopolamine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Transdermal Scopolamine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Transdermal Scopolamine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Baxter International
GlaxoSmithKline
Novartis AG
Perrigo Company
Caleb Pharmaceuticals
Myungmoon Pharma
Pfizer
Nichi-Iko
Segment by Type
Tablet Type
Syrups Type
Injections Type
Patch Type
Gel Type
Segment by Application
Narcotic Analgesia
Cough
Asthma
Motion Sickness
Parkinson's Disease
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Transdermal Scopolamine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Transdermal Scopolamine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Transdermal Scopolamine Market Overview
1.1 Product Definition
1.2 Transdermal Scopolamine by Type
1.2.1 Global Transdermal Scopolamine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Tablet Type
1.2.3 Syrups Type
1.2.4 Injections Type
1.2.5 Patch Type
1.2.6 Gel Type
1.3 Transdermal Scopolamine by Application
1.3.1 Global Transdermal Scopolamine Market Value by Application (2024 VS 2031)
1.3.2 Narcotic Analgesia
1.3.3 Cough
1.3.4 Asthma
1.3.5 Motion Sickness
1.3.6 Parkinson's Disease
1.3.7 Others
1.4 Global Transdermal Scopolamine Market Size Estimates and Forecasts
1.4.1 Global Transdermal Scopolamine Revenue 2020-2031
1.4.2 Global Transdermal Scopolamine Sales 2020-2031
1.4.3 Global Transdermal Scopolamine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Transdermal Scopolamine Market Competition by Manufacturers
2.1 Global Transdermal Scopolamine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Transdermal Scopolamine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Transdermal Scopolamine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Transdermal Scopolamine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Transdermal Scopolamine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Transdermal Scopolamine, Product Type & Application
2.7 Global Key Manufacturers of Transdermal Scopolamine, Date of Enter into This Industry
2.8 Global Transdermal Scopolamine Market Competitive Situation and Trends
2.8.1 Global Transdermal Scopolamine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Transdermal Scopolamine Players Market Share by Revenue
2.8.3 Global Transdermal Scopolamine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Transdermal Scopolamine Market Scenario by Region
3.1 Global Transdermal Scopolamine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Transdermal Scopolamine Sales by Region: 2020-2031
3.2.1 Global Transdermal Scopolamine Sales by Region: 2020-2025
3.2.2 Global Transdermal Scopolamine Sales by Region: 2026-2031
3.3 Global Transdermal Scopolamine Revenue by Region: 2020-2031
3.3.1 Global Transdermal Scopolamine Revenue by Region: 2020-2025
3.3.2 Global Transdermal Scopolamine Revenue by Region: 2026-2031
3.4 North America Transdermal Scopolamine Market Facts & Figures by Country
3.4.1 North America Transdermal Scopolamine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Transdermal Scopolamine Sales by Country (2020-2031)
3.4.3 North America Transdermal Scopolamine Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Transdermal Scopolamine Market Facts & Figures by Country
3.5.1 Europe Transdermal Scopolamine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Transdermal Scopolamine Sales by Country (2020-2031)
3.5.3 Europe Transdermal Scopolamine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Transdermal Scopolamine Market Facts & Figures by Region
3.6.1 Asia Pacific Transdermal Scopolamine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Transdermal Scopolamine Sales by Region (2020-2031)
3.6.3 Asia Pacific Transdermal Scopolamine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Transdermal Scopolamine Market Facts & Figures by Country
3.7.1 Latin America Transdermal Scopolamine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Transdermal Scopolamine Sales by Country (2020-2031)
3.7.3 Latin America Transdermal Scopolamine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Transdermal Scopolamine Market Facts & Figures by Country
3.8.1 Middle East and Africa Transdermal Scopolamine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Transdermal Scopolamine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Transdermal Scopolamine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Transdermal Scopolamine Sales by Type (2020-2031)
4.1.1 Global Transdermal Scopolamine Sales by Type (2020-2025)
4.1.2 Global Transdermal Scopolamine Sales by Type (2026-2031)
4.1.3 Global Transdermal Scopolamine Sales Market Share by Type (2020-2031)
4.2 Global Transdermal Scopolamine Revenue by Type (2020-2031)
4.2.1 Global Transdermal Scopolamine Revenue by Type (2020-2025)
4.2.2 Global Transdermal Scopolamine Revenue by Type (2026-2031)
4.2.3 Global Transdermal Scopolamine Revenue Market Share by Type (2020-2031)
4.3 Global Transdermal Scopolamine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Transdermal Scopolamine Sales by Application (2020-2031)
5.1.1 Global Transdermal Scopolamine Sales by Application (2020-2025)
5.1.2 Global Transdermal Scopolamine Sales by Application (2026-2031)
5.1.3 Global Transdermal Scopolamine Sales Market Share by Application (2020-2031)
5.2 Global Transdermal Scopolamine Revenue by Application (2020-2031)
5.2.1 Global Transdermal Scopolamine Revenue by Application (2020-2025)
5.2.2 Global Transdermal Scopolamine Revenue by Application (2026-2031)
5.2.3 Global Transdermal Scopolamine Revenue Market Share by Application (2020-2031)
5.3 Global Transdermal Scopolamine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Baxter International
6.1.1 Baxter International Company Information
6.1.2 Baxter International Description and Business Overview
6.1.3 Baxter International Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Baxter International Transdermal Scopolamine Product Portfolio
6.1.5 Baxter International Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Company Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GlaxoSmithKline Transdermal Scopolamine Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Novartis AG
6.3.1 Novartis AG Company Information
6.3.2 Novartis AG Description and Business Overview
6.3.3 Novartis AG Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis AG Transdermal Scopolamine Product Portfolio
6.3.5 Novartis AG Recent Developments/Updates
6.4 Perrigo Company
6.4.1 Perrigo Company Company Information
6.4.2 Perrigo Company Description and Business Overview
6.4.3 Perrigo Company Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Perrigo Company Transdermal Scopolamine Product Portfolio
6.4.5 Perrigo Company Recent Developments/Updates
6.5 Caleb Pharmaceuticals
6.5.1 Caleb Pharmaceuticals Company Information
6.5.2 Caleb Pharmaceuticals Description and Business Overview
6.5.3 Caleb Pharmaceuticals Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Caleb Pharmaceuticals Transdermal Scopolamine Product Portfolio
6.5.5 Caleb Pharmaceuticals Recent Developments/Updates
6.6 Myungmoon Pharma
6.6.1 Myungmoon Pharma Company Information
6.6.2 Myungmoon Pharma Description and Business Overview
6.6.3 Myungmoon Pharma Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Myungmoon Pharma Transdermal Scopolamine Product Portfolio
6.6.5 Myungmoon Pharma Recent Developments/Updates
6.7 Pfizer
6.7.1 Pfizer Company Information
6.7.2 Pfizer Description and Business Overview
6.7.3 Pfizer Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Pfizer Transdermal Scopolamine Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Nichi-Iko
6.8.1 Nichi-Iko Company Information
6.8.2 Nichi-Iko Description and Business Overview
6.8.3 Nichi-Iko Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Nichi-Iko Transdermal Scopolamine Product Portfolio
6.8.5 Nichi-Iko Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Transdermal Scopolamine Industry Chain Analysis
7.2 Transdermal Scopolamine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Transdermal Scopolamine Production Mode & Process Analysis
7.4 Transdermal Scopolamine Sales and Marketing
7.4.1 Transdermal Scopolamine Sales Channels
7.4.2 Transdermal Scopolamine Distributors
7.5 Transdermal Scopolamine Customer Analysis
8 Transdermal Scopolamine Market Dynamics
8.1 Transdermal Scopolamine Industry Trends
8.2 Transdermal Scopolamine Market Drivers
8.3 Transdermal Scopolamine Market Challenges
8.4 Transdermal Scopolamine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Transdermal Scopolamine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Transdermal Scopolamine Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Transdermal Scopolamine Market Competitive Situation by Manufacturers in 2024
Table 4. Global Transdermal Scopolamine Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Transdermal Scopolamine Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Transdermal Scopolamine Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Transdermal Scopolamine Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Transdermal Scopolamine Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Transdermal Scopolamine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Transdermal Scopolamine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Transdermal Scopolamine, Product Type & Application
Table 12. Global Key Manufacturers of Transdermal Scopolamine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Transdermal Scopolamine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transdermal Scopolamine as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Transdermal Scopolamine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Transdermal Scopolamine Sales by Region (2020-2025) & (K Units)
Table 18. Global Transdermal Scopolamine Sales Market Share by Region (2020-2025)
Table 19. Global Transdermal Scopolamine Sales by Region (2026-2031) & (K Units)
Table 20. Global Transdermal Scopolamine Sales Market Share by Region (2026-2031)
Table 21. Global Transdermal Scopolamine Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Transdermal Scopolamine Revenue Market Share by Region (2020-2025)
Table 23. Global Transdermal Scopolamine Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Transdermal Scopolamine Revenue Market Share by Region (2026-2031)
Table 25. North America Transdermal Scopolamine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Transdermal Scopolamine Sales by Country (2020-2025) & (K Units)
Table 27. North America Transdermal Scopolamine Sales by Country (2026-2031) & (K Units)
Table 28. North America Transdermal Scopolamine Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Transdermal Scopolamine Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Transdermal Scopolamine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Transdermal Scopolamine Sales by Country (2020-2025) & (K Units)
Table 32. Europe Transdermal Scopolamine Sales by Country (2026-2031) & (K Units)
Table 33. Europe Transdermal Scopolamine Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Transdermal Scopolamine Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Transdermal Scopolamine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Transdermal Scopolamine Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Transdermal Scopolamine Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Transdermal Scopolamine Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Transdermal Scopolamine Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Transdermal Scopolamine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Transdermal Scopolamine Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Transdermal Scopolamine Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Transdermal Scopolamine Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Transdermal Scopolamine Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Transdermal Scopolamine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Transdermal Scopolamine Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Transdermal Scopolamine Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Transdermal Scopolamine Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Transdermal Scopolamine Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Transdermal Scopolamine Sales (K Units) by Type (2020-2025)
Table 51. Global Transdermal Scopolamine Sales (K Units) by Type (2026-2031)
Table 52. Global Transdermal Scopolamine Sales Market Share by Type (2020-2025)
Table 53. Global Transdermal Scopolamine Sales Market Share by Type (2026-2031)
Table 54. Global Transdermal Scopolamine Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Transdermal Scopolamine Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Transdermal Scopolamine Revenue Market Share by Type (2020-2025)
Table 57. Global Transdermal Scopolamine Revenue Market Share by Type (2026-2031)
Table 58. Global Transdermal Scopolamine Price (USD/Unit) by Type (2020-2025)
Table 59. Global Transdermal Scopolamine Price (USD/Unit) by Type (2026-2031)
Table 60. Global Transdermal Scopolamine Sales (K Units) by Application (2020-2025)
Table 61. Global Transdermal Scopolamine Sales (K Units) by Application (2026-2031)
Table 62. Global Transdermal Scopolamine Sales Market Share by Application (2020-2025)
Table 63. Global Transdermal Scopolamine Sales Market Share by Application (2026-2031)
Table 64. Global Transdermal Scopolamine Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Transdermal Scopolamine Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Transdermal Scopolamine Revenue Market Share by Application (2020-2025)
Table 67. Global Transdermal Scopolamine Revenue Market Share by Application (2026-2031)
Table 68. Global Transdermal Scopolamine Price (USD/Unit) by Application (2020-2025)
Table 69. Global Transdermal Scopolamine Price (USD/Unit) by Application (2026-2031)
Table 70. Baxter International Company Information
Table 71. Baxter International Description and Business Overview
Table 72. Baxter International Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 73. Baxter International Transdermal Scopolamine Product
Table 74. Baxter International Recent Developments/Updates
Table 75. GlaxoSmithKline Company Information
Table 76. GlaxoSmithKline Description and Business Overview
Table 77. GlaxoSmithKline Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. GlaxoSmithKline Transdermal Scopolamine Product
Table 79. GlaxoSmithKline Recent Developments/Updates
Table 80. Novartis AG Company Information
Table 81. Novartis AG Description and Business Overview
Table 82. Novartis AG Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. Novartis AG Transdermal Scopolamine Product
Table 84. Novartis AG Recent Developments/Updates
Table 85. Perrigo Company Company Information
Table 86. Perrigo Company Description and Business Overview
Table 87. Perrigo Company Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Perrigo Company Transdermal Scopolamine Product
Table 89. Perrigo Company Recent Developments/Updates
Table 90. Caleb Pharmaceuticals Company Information
Table 91. Caleb Pharmaceuticals Description and Business Overview
Table 92. Caleb Pharmaceuticals Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. Caleb Pharmaceuticals Transdermal Scopolamine Product
Table 94. Caleb Pharmaceuticals Recent Developments/Updates
Table 95. Myungmoon Pharma Company Information
Table 96. Myungmoon Pharma Description and Business Overview
Table 97. Myungmoon Pharma Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Myungmoon Pharma Transdermal Scopolamine Product
Table 99. Myungmoon Pharma Recent Developments/Updates
Table 100. Pfizer Company Information
Table 101. Pfizer Description and Business Overview
Table 102. Pfizer Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Pfizer Transdermal Scopolamine Product
Table 104. Pfizer Recent Developments/Updates
Table 105. Nichi-Iko Company Information
Table 106. Nichi-Iko Description and Business Overview
Table 107. Nichi-Iko Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 108. Nichi-Iko Transdermal Scopolamine Product
Table 109. Nichi-Iko Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Transdermal Scopolamine Distributors List
Table 113. Transdermal Scopolamine Customers List
Table 114. Transdermal Scopolamine Market Trends
Table 115. Transdermal Scopolamine Market Drivers
Table 116. Transdermal Scopolamine Market Challenges
Table 117. Transdermal Scopolamine Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Product Picture of Transdermal Scopolamine
Figure 2. Global Transdermal Scopolamine Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Transdermal Scopolamine Market Share by Type: 2024 & 2031
Figure 4. Tablet Type Product Picture
Figure 5. Syrups Type Product Picture
Figure 6. Injections Type Product Picture
Figure 7. Patch Type Product Picture
Figure 8. Gel Type Product Picture
Figure 9. Global Transdermal Scopolamine Market Value by Application (2020-2031) & (US$ Million)
Figure 10. Global Transdermal Scopolamine Market Share by Application: 2024 & 2031
Figure 11. Narcotic Analgesia
Figure 12. Cough
Figure 13. Asthma
Figure 14. Motion Sickness
Figure 15. Parkinson's Disease
Figure 16. Others
Figure 17. Global Transdermal Scopolamine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Transdermal Scopolamine Market Size (2020-2031) & (US$ Million)
Figure 19. Global Transdermal Scopolamine Sales (2020-2031) & (K Units)
Figure 20. Global Transdermal Scopolamine Average Price (USD/Unit) & (2020-2031)
Figure 21. Transdermal Scopolamine Report Years Considered
Figure 22. Transdermal Scopolamine Sales Share by Manufacturers in 2024
Figure 23. Global Transdermal Scopolamine Revenue Share by Manufacturers in 2024
Figure 24. Global 5 and 10 Largest Transdermal Scopolamine Players: Market Share by Revenue in Transdermal Scopolamine in 2024
Figure 25. Transdermal Scopolamine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 26. Global Transdermal Scopolamine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 27. North America Transdermal Scopolamine Sales Market Share by Country (2020-2031)
Figure 28. North America Transdermal Scopolamine Revenue Market Share by Country (2020-2031)
Figure 29. U.S. Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. Canada Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Europe Transdermal Scopolamine Sales Market Share by Country (2020-2031)
Figure 32. Europe Transdermal Scopolamine Revenue Market Share by Country (2020-2031)
Figure 33. Germany Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. France Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. U.K. Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Italy Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. Russia Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Asia Pacific Transdermal Scopolamine Sales Market Share by Region (2020-2031)
Figure 39. Asia Pacific Transdermal Scopolamine Revenue Market Share by Region (2020-2031)
Figure 40. China Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Japan Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. South Korea Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. India Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Australia Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. China Taiwan Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Indonesia Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Thailand Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Malaysia Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Latin America Transdermal Scopolamine Sales Market Share by Country (2020-2031)
Figure 50. Latin America Transdermal Scopolamine Revenue Market Share by Country (2020-2031)
Figure 51. Mexico Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Brazil Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Argentina Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Middle East and Africa Transdermal Scopolamine Sales Market Share by Country (2020-2031)
Figure 55. Middle East and Africa Transdermal Scopolamine Revenue Market Share by Country (2020-2031)
Figure 56. Turkey Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Saudi Arabia Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. UAE Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 59. Global Sales Market Share of Transdermal Scopolamine by Type (2020-2031)
Figure 60. Global Revenue Market Share of Transdermal Scopolamine by Type (2020-2031)
Figure 61. Global Transdermal Scopolamine Price (USD/Unit) by Type (2020-2031)
Figure 62. Global Sales Market Share of Transdermal Scopolamine by Application (2020-2031)
Figure 63. Global Revenue Market Share of Transdermal Scopolamine by Application (2020-2031)
Figure 64. Global Transdermal Scopolamine Price (USD/Unit) by Application (2020-2031)
Figure 65. Transdermal Scopolamine Value Chain
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
